Back

Active Clinical Trial Studies

UF Health Cancer Center – Orlando Health

For more information:

321.841.1620

Clinical Trials

Below is a list of currently active Phase II, III and IV trials. You can also search for a specific clinical trial using the field provided above.

  • Combo Chemo With or Without Torisel Treating Rhabdomyosarcoma

    To compare the EFS and the OS of patients with IR RMS treated with surgery , radiotherapy , and Vac alternating with VI(VAC/VI) to that of patients treated with surgery , radiotherapy and VAC/VI plus temsirolimus (TORI) To compare the outcome of patietns based on their FOXO1 fusioin gene partener by evaluating PAX3 vs PAX7 in all patients found to be FOXO1 fusion positive . To compare the outcome of patients based on their FDG-PET response at Week 9 ( positive or negative ) , as assessed by Deauville Criteria

  • Blinatumomab in Treating Younger Patients W/Relapsed B-cell ALL

    Primary Aims To compare disease free survival (DFS) of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). To compare DFS of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). Secondary Aims To compare overall survival (OS) of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5 week blocks of blinatumomab (HR/IR Randomization). To compare OS of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization Exploratory Aims To compare the rates of MRD ≥ 0.01% at the end of Block 2 and Block 3 for HR and IR relapse B-ALL patients in HR/IR randomization. To estimate, for treatment failure (TF) patients not previously receiving blinatumomab, the hematologic complete remission rate (CR), rate of MRD < 0.01%, and proportion able to proceed to hematopoietic stem cell transplant (HSCT) in CR after treatment with blinatumomab. To assess the feasibility and safety of rapid taper of immune suppression for the subset of HSCT patients with MRD ≥ 0.01% pre- and/or post-HSCT with no acute graft versus host disease (aGVHD). To evaluate blinatumomab pharmacokinetics (PK) and explore exposure-response relationships for measures of safety and effectiveness.

  • Therapy for Down syndrome kids with AML

    To determine the 2-year event-free-survival (EFS) for children with standard risk DS AML (MRD-negative after one cycle of induction therapy) after elimination of HD Ara-C from the treatment regimen. To determine the 2-year EFS for children with high risk DS AML (MRD-positive after one cycle of induction therapy) after intensification of treatment equivalent to that used for high risk AML in children without DS.

  • Long-term Safety and Efficacy Study of Adalimumab in Pediatric Su

    This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.

  • Dinutuximab in Combo w/ Sargramostim for Recurrent Osteosarcoma

    This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent). Dinutuximab is a type of drug called a monoclonal antibody. It is designed to recognize a specific target on the surface of cancer cells. It then attaches to the cancer cells and kills them, without harming normal cells. Sargramostim may help the body increase the amount of white blood cells it produces, which help the body fight off infections. Giving sargramostim with dinutuximab may help the dinutuximab work better and kill more cancer cells.

  • GM-CSF in Incompletely Resected or Recurrent Ependymoma

    This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma.

  • Study of the safety and PK of Cobimetinib Pts with Solid Tumors

    This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable and for which no curative standard-of-care treatment options exist. The study will be conducted in two stages: a dose-escalation stage and an expansion stage at the recommended dose.

  • A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma

    This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent). Dinutuximab is a type of drug called a monoclonal antibody. It is designed to recognize a specific target on the surface of cancer cells. It then attaches to the cancer cells and kills them, without harming normal cells. Sargramostim may help the body increase the amount of white blood cells it produces, which help the body fight off infections. Giving sargramostim with dinutuximab may help the dinutuximab work better and kill more cancer cells.

  • Pilot Study of the Effect of GM-CSF on Macrophages in Incompletely Resected or Recurrent Ependymoma

    This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma.

  • A Study to Evaluate the Safety and Efficacy of VX-371 in Subject

    The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in saline compared to saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-CFTR mutation, and being treated with Orkambi